- cafead   May 17, 2018 at 09:52: AM
via
article source
- Exelixis will receive a milestone payment of $50 million
- Approval based on Cabometyx vs versus sunitinib in CABOSUN trial
- Cabometyx was approved for reimbursement in most European countries by May of 2018
article source